SunRegen Healthcare AG, a Basel-based Swiss biopharmaceutical innovator, is pioneering therapies for severe ophthalmic and neurological disorders with high unmet needs. Our lead candidate targets Retinitis Pigmentosa (RP)—a rare genetic disease lacking disease-modifying treatments—and is under evaluation for broader retinal neurodegenerative conditions, including dry AMD and Optic Atrophy, which collectively impact millions globally. Strategically centered on rare diseases with blockbuster potential, we aim to achieve rapid regulatory and commercial traction before expanding into larger indications in ophthalmology and neurology. Supported by Basel’s life sciences ecosystem, SunRegen combines scientific rigor with scalable market opportunities, offering investors a compelling stake in transformative therapies poised to deliver patient impact and sustainable growth. Innovating for vision, advancing for life.
Technology
Additional questions
Other Place of Business
Project
A breakthrough therapy project for the treatment of neurodegeneration to unlock a $60B+ market
The world’s first oral neuro-rescuing therapy with the potential to treat retinal and CNS neurodegenerative diseases.